Most patients receiving a GLP-1 receptor agonist (RA) and a biologic continue co-therapy for over a year with few treatment-related adverse events.
Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback